Category: Regulatory DisclosuresBy adminMay 31, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires fast-growing molecule with an established market presenceNextNext post:Disclosure to EGX regarding molecule acquisitionRelated PostsRameda Announces New Chairman and Additions to its Board of DirectorsJune 3, 2026Rameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024
